Inside Bayer’s $2.45bn push to defend its ophthalmology franchise
Eylea is under pressure. Bayer’s $2.45bn Perfuse bet tests whether PER-001 can carry its next ophthalmology growth story.
Could Kodiak’s KSI-101 become the first real biologic challenger in inflammatory eye disease?
Steroids still dominate MESI care. Kodiak’s KSI-101 may test whether local biologics can change inflammatory retina treatment.
One-time gene therapy approach from Ocugen gains traction in dry AMD pipeline race
Ocugen reports positive phase 2 data for OCU410 in geographic atrophy. Learn what this means for retinal care, regulation, and future gene therapy adoption.
Extended-interval nAMD therapy gets a new contender as Innovent Biologics posts Phase 3 STAR data
Innovent Biologics’ efdamrofusp alfa cleared a key Phase 3 nAMD hurdle in China. Read what the STAR data could change for retinal treatment.
What GenSight Biologics’ French CUA decision means for LHON gene therapy
France grants compassionate use access to GenSight Biologics’ LUMEVOQ for LHON. Explore what this decision changes and what risks remain.